About the Bristol-Myers Squibb/Pfizer Collaboration: In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb (registered as ELIQUIS®, indicated in Australia for stroke prevention in non valvular atrial fibrillation and the treatment and prevention of recurrence of venous thromboembolic (VTE) events in adult patients). This global alliance combines Bristol-Myers Squibb’s long-standing strengths in cardiovascular drug development and commercialization with Pfizer’s global scale and expertise in this field.